| Sokaogon Chippewa Community | |
|
3144 Vanzile Rd Crandon WI 54520-8149 | |
| (715) 478-5180 | |
| (715) 478-5904 |
| Full Name | Sokaogon Chippewa Community |
|---|---|
| Speciality | Clinic/Center |
| Location | 3144 Vanzile Rd, Crandon, Wisconsin |
| Authorized Official Name and Position | Leah Newton (BILLING MANAGER) |
| Authorized Official Contact | 7156220293 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Sokaogon Chippewa Community 3144 Vanzile Rd Crandon WI 54520-8149 Ph: (715) 478-5180 | Sokaogon Chippewa Community 3144 Vanzile Rd Crandon WI 54520-8149 Ph: (715) 478-5180 |
| NPI Number | 1033115456 |
|---|---|
| Provider Enumeration Date | 06/21/2005 |
| Last Update Date | 09/01/2022 |
| Medicare PECOS PAC ID | 1759370869 |
|---|---|
| Medicare Enrollment ID | O20040512000238 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033115456 | NPI | - | NPPES |
| 32957000 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | 32957000 (Wisconsin) | Primary |
| Provider Name | Shannon S Meyer |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1316933542 PECOS PAC ID: 4486550613 Enrollment ID: I20031209000837 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Richard A Brandner |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1598954398 PECOS PAC ID: 8527049931 Enrollment ID: I20040601000039 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Gary M Pusateri |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1851383525 PECOS PAC ID: 2668408071 Enrollment ID: I20050715000938 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Eunice Corujo Incha |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1255371837 PECOS PAC ID: 9931125994 Enrollment ID: I20051019000215 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Sylvia J Dennison |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1700838836 PECOS PAC ID: 6709897937 Enrollment ID: I20060531000211 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Allen Craig Orth |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1073548517 PECOS PAC ID: 3870597545 Enrollment ID: I20060912000158 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Suzette L Katchko |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073773677 PECOS PAC ID: 4880758721 Enrollment ID: I20090121000668 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Stephanie Coons |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1467733576 PECOS PAC ID: 0042460313 Enrollment ID: I20121022000728 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Bobbi Jo K Bissonette |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366874489 PECOS PAC ID: 1355575184 Enrollment ID: I20131010001708 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Steven Craig Miszkiewicz |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1548257249 PECOS PAC ID: 1456343128 Enrollment ID: I20170215001536 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Melinda Roth |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154757045 PECOS PAC ID: 5698900231 Enrollment ID: I20170920002093 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Abigail B Ashbeck |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1437827441 PECOS PAC ID: 4789048943 Enrollment ID: I20230907000493 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
| Provider Name | Lynette M Mccorkle |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1609115682 PECOS PAC ID: 7416305727 Enrollment ID: I20240228002465 |
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
News Archive
Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
The UK's leading bowel cancer research charity, Bowel Cancer UK, and the Royal College of Pathologists have today published findings which show that people under 50 diagnosed with bowel cancer are not being tested for Lynch syndrome – a genetic condition that increases the risk of bowel cancer by 80 per cent.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.
125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.
› Verified 4 days ago
Aspirus Crandon Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 400 W Glen St, Crandon, WI 54520 Phone: 715-478-3318 | |
Northwoods Behavioral Health Center, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 600 W Broad St, Crandon, WI 54520 Phone: 920-217-7910 | |
The Center For Human Restoration, Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 505 W Glen St Ste 1, Crandon, WI 54520 Phone: 715-478-5202 Fax: 715-478-5205 |